OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. Other stock markets 07/04/2025			5-day change	1st Jan Change
1,651.00 ^KRW	-13.92%		-.--%	-

12-28	OLIPASS Corporation announced that it has received KRW 600 million in funding	CI
12-17	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding	CI

Market Cap	26.53B 17.54M 15.12M 13.91M 13.05M 24.52M 1.66B 24.76M 164M 64.24M 812M 65.81M 64.42M 2.81B	P/E Ratio 2021	-10.8x	P/E Ratio 2022	-7.66x
Enterprise Value	20.34B 13.44M 11.59M 10.66M 10M 18.79M 1.27B 18.98M 126M 49.24M 622M 50.45M 49.38M 2.15B	EV / Sales 2021	295x	EV / Sales 2022	79x
Free-Float	48.85%	Yield 2021 *	-	Yield 2022	-

12-28	OLIPASS Corporation announced that it has received KRW 600 million in funding	CI
12-17	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding	CI
12-07	OLIPASS Corporation announced that it has received KRW 739 million in funding from Genocure Co., Ltd. and other investors.	CI
11-27	OLIPASS Corporation announced that it expects to receive KRW 739 million in funding from Genocure Co., Ltd. and other investors	CI
11-20	OLIPASS Corporation announced that it has received KRW 600 million in funding from Genocure Co., Ltd.	CI
11-12	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding from Genocure Co., Ltd.	CI
24/06/25	OLIPASS Corporation cancelled the transaction announced on December 6, 2024	CI
31/03/25	OLIPASS Corporation announced that it has received KRW 2 billion in funding	CI
30/03/25	OLIPASS Corporation announced that it expects to receive KRW 2 billion in funding	CI
26/12/24	OLIPASS Corporation announced that it has received KRW 3.0000031 billion in funding from Invest Partners No. 1	CI
05/12/24	OLIPASS Corporation announced that it expects to receive KRW 19.99998708 billion in funding	CI
12/11/24	OLIPASS Corporation announced that it expects to receive KRW 3.0000031 billion in funding from Invest Partners No. 1	CI
27/08/24	OLIPASS Corporation announced that it has received KRW 5.500000471 billion in funding from Infraflex Ltd, Thecity Co., Ltd., Optimum New Growth Fund	CI

3 years	1,568	34,500
5 years	1,568	158,000
10 years	1,568	240,666.67

OLIPASS Corporation Share Price

Stocks

A244460

KR7244460002

Biotechnology & Medical Research

Valuation: OLIPASS Corporation

Latest news : OLIPASS Corporation

Quotes and Performance

Course Extremes

Managers and Directors: OLIPASS Corporation

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Tae-Hyun Kim CEO	Chief Executive Officer	54	21/05/2025
Bo-Kyung Oh PRN	Corporate Officer/Principal	34	27/11/2024
Ki-Won Son AUD	Comptroller/Controller/Auditor	67	30/03/2025

Director	Title	Age	Since
Tae-Hyun Kim BRD	Director/Board Member	54	27/11/2024
Bo-Kyung Oh BRD	Director/Board Member	34	27/11/2024
Young-Kwang Nam BRD	Director/Board Member	66	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OLIPASS CORPORATION	-13.92%	-.--%	-.--%	-92.21%	9.24M
ARGENX SE	-2.86%	-0.26%	+57.57%	+110.98%	56.42B
WUXI APPTEC CO., LTD.	-0.34%	+2.91%	+45.55%	+46.87%	44.54B
BIONTECH SE	+0.44%	+6.55%	-14.32%	-19.38%	22.9B
INSMED INCORPORATED	+0.11%	+4.27%	-3.34%	+390.73%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	-0.51%	-5.56%	+10.43%	-29.97%	16.4B
GENMAB A/S	-1.54%	-1.06%	+8.10%	-39.28%	15.4B
EXELIXIS, INC.	-0.82%	+1.96%	+26.36%	+176.20%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.96%	+6.56%	+20.81%	-	12.36B
PHARMAESSENTIA CORPORATION	+0.32%	+1.60%	+96.37%	+207.56%	11.15B
Average	-1.81%	-3.09%	+24.75%	+83.50%	21.37B
Weighted average by Cap.	-0.88%	+2.54%	+32.09%	+98.14%

	2021	2022
Net sales	852M 563K 485K 447K 419K 787K 53.21M 795K 5.28M 2.06M 26.06M 2.11M 2.07M 90.17M	2.3B 1.52M 1.31M 1.2M 1.13M 2.12M 143M 2.14M 14.23M 5.56M 70.24M 5.7M 5.58M 243M
Net income	-25.13B -16.62M -14.32M -13.18M -12.36M -23.23M -1.57B -23.46M -156M -60.86M -769M -62.35M -61.03M -2.66B	-24.17B -15.98M -13.77M -12.67M -11.89M -22.33M -1.51B -22.55M -150M -58.52M -739M -59.95M -58.68M -2.56B
Net Debt	-18.29B -12.09M -10.42M -9.59M -9M -16.9M -1.14B -17.07M -113M -44.29M -560M -45.37M -44.41M -1.94B	-6.2B -4.1M -3.53M -3.25M -3.05M -5.72M -387M -5.78M -38.4M -15M -190M -15.37M -15.04M -656M